Focused on powering the future of multi-dose preservative free ocular drug delivery.
As we continue to witness the ageing of the global population, we also see the increase in prevalence of age-related diseases such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO) and Glaucoma.
As a result, ophthalmic drug delivery continues to grow in prominence, thanks to its patient centric design and accurate dosing it ensures high levels of patient compliance.
With over two decades experience and expertise in providing sterile manufacturing excellence, we aim to be your strategic development partner of choice for ophthalmic drug delivery, guiding products from early-stage research right through to the clinic and onto commercialisation.
Multi-dose preservative free devices offer pharmaceutical partners tangible benefits; being a proven delivery solution that supports product differentiation and patient safety. Our comprehensive development services support our partners in formulation and product development for solutions, suspensions and emulsions. Our expert team also conduct device selection studies, method development as well as sterility and stability testing.
For partners in early and mid-phase clinical programmes our clinical filling capabilities are designed to fill multidose preservative free systems, utilising isolator technology and a semi-automated filling process.

Key Benefits for Pharmaceutical Partners
Key Benefits for Patients



